The Oncology Institute, Inc.

The Oncology Institute, Inc. (TOI) reported total operating revenue of $502.7 million for FY 2025, representing a 27.8% increase from the prior year. This growth was driven by a 49.6% increase in specialty pharmacy revenue to $269.2 million and an 11.8% increase in patient services revenue to $229.0 million. However, the company incurred a net loss of $60.6 million, an improvement from a $64.7 million loss in FY 2024. The loss from operations was $36.1 million. The company ended the year with $33.6 million in cash and cash equivalents, a decrease of $16.1 million from the prior year, and had total assets of $164.7 million against total liabilities of $180.4 million, resulting in a stockholders' equity deficit of $15.7 million. More than 46% of revenue was generated from value-based contracts.

Key Takeaways